Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma Reports Second Quarter 2018 Results

Recent Highlights Include Completion of Enrollment of MPOWERED Phase 3 Trial and 50% Randomization in CHIASMA OPTIMAL Phase 3 Trial WALTHAM, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc....
July 25, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma Completes Enrollment of MPOWERED(TM) Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

Chiasma Anticipates Trial Completion in Q4 2019 and Release of Top-line MPOWERED Data by Early 2020 WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage...
June 18, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference

WALTHAM, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
June 14, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
May 14, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial

WALTHAM, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
May 10, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma Reports First Quarter 2018 Results

WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
March 20, 2018 16:05 ET | Source: Chiasma, Inc.

Chiasma Reports Fourth Quarter and Year End 2017 Results

WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
March 16, 2018 08:00 ET | Source: Chiasma, Inc.

Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly

WALTHAM, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
March 05, 2018 08:00 ET | Source: Chiasma, Inc.

Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
February 28, 2018 08:45 ET | Source: Chiasma, Inc.

Chiasma Honors Patients, Researchers for Rare Disease Day 2018

WALTHAM, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...